HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Refractory coccidioidomycosis treated with posaconazole.

AbstractBACKGROUND:
Disseminated coccidioidomycosis (which is caused by the endemic fungi of the genus Coccidioides) can be a life-threatening systemic fungal infection. Although conventional antifungal therapies have activity against Coccidioides, the disease can be refractory to standard therapies. Drug-associated toxicities also may limit the clinical utility of the standard antifungal drugs. In addition, relapses in patients with disseminated coccidioidomycosis are common, making long-term management of this disease challenging.
METHODS:
We report the outcomes of 6 patients with coccidioidomycosis who were treated with posaconazole salvage therapy after treatment with conventional antifungal therapies failed to produce sustained clinical improvement. Patients were administered posaconazole oral suspension 800 mg/day in divided doses as part of an open-label clinical trial. A modified version of the Mycoses Study Group Coccidioides scoring system was used to evaluate the burden of disease. Posaconazole therapy resulted in rapid clinical improvements in the signs and symptoms of coccidioidomycosis.
RESULTS:
At the end of therapy, 5 of 6 patients had successful outcomes. Posaconazole was well tolerated despite long-term administration (1-2 years), and 2 patients continued to receive posaconazole maintenance therapy at the time of writing.
CONCLUSIONS:
The successful outcomes observed in this case series suggest that posaconazole is an effective therapy for coccidioidomycosis.
AuthorsGregory M Anstead, Gavin Corcoran, James Lewis, Deborah Berg, John R Graybill
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 40 Issue 12 Pg. 1770-6 (Jun 15 2005) ISSN: 1537-6591 [Electronic] United States
PMID15909265 (Publication Type: Case Reports, Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Antifungal Agents
  • Triazoles
  • posaconazole
Topics
  • Adolescent
  • Adult
  • Antifungal Agents (therapeutic use)
  • Coccidioidomycosis (drug therapy, pathology)
  • Dermatomycoses (drug therapy, pathology)
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Middle Aged
  • Skin (pathology)
  • Triazoles (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: